TScan Therapeutics, Inc.

NASDAQ:TCRX

Biotechnology

Healthcare
$0.82 +2.23%

+$0.02 today

Market cap
$50.37M
Beta
1.03
P/E (TTM)
-1.0
EPS (TTM)
-$0.96
52W Low $0.85High $2.57

Volume 0.00M

Average 0.81M

TCRX Interest Expense

Cost of servicing the company's debt during the period.

TScan Therapeutics, Inc.NASDAQ: TCRX

Interest Expense · Q1 FY2026 · quarter ended Mar 2026

Interest expense growth accelerates

Q1 FY2026 interest expense of $689K rose 1.5% year over year, ahead of the -17.6% change in trailing-twelve-month interest expense. Sequentially, it fell 1.9% from the prior quarter. Over 3 fiscal years it compounded at +33.0% a year.

Context

  • Interest expense amounted to 26.8% of revenue in FY2025, down 102.9 pp from a year earlier.
  • Interest expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly growth of +1.5% holds above the trailing-twelve-month pace of -17.6%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$689K-1.9% QoQ
Last fiscal yearDec 2025
$2.77M-24.2% YoY
LTMMar 2026
$2.78M-17.6% YoY
Interest Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+1.5%——
1 year-24.2%——
3-year CAGR+33.0%——
5-year CAGR——
10-year CAGR——

Interest Expense history

USD · from the income statement

Latest · FY2025
2.77M USD
Year-over-year change
-24.2%

Interest Expense vs competitors

How TCRX compares with its peers on the latest reported figures

  • TCRX's LTM Mar 2026 interest expense of $2.78M is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -17.6% is the 3rd highest of 6, against a peer median of -26.3%.
  • Interest expense amounts to 30.4% of revenue for TCRX, versus a peer median of 1.2%.
TCRX Competitors Peer median
Interest Expense for TCRX and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$9.57M -28.8%-13.9%14.5%
TCRXTScan Therapeutics, Inc.LTM Mar 2026$2.78M -17.6%+33.0%30.4%
VXRTVaxart, Inc.LTM Mar 2026$2.33M -26.3%+29.3%0.9%
ACETAdicet Bio, Inc.LTM Mar 2026$59K +2850.0%-23.4%—
NTRBNutriband Inc.LTM Apr 2026$21.66K +16.0%+39.6%1.2%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
IMUXImmunic, Inc.LTM Mar 2026$0 ———
XBITXBiotech Inc.LTM Mar 2026$0 -100.0%——
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
Peer median (excluding TCRX) $0-26.3%+7.7%1.2%

Competitors are the stored peer set for TCRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue10.14M13.54M21.05M2.82M10.33M
Cost of Revenue00002.87M
Gross Profit10.14M13.54M21.05M2.82M7.46M
Gross Margin100.0%100.0%100.0%100.0%72.2%
Research & Development44.95M59.82M88.15M107.35M114.15M
Selling, General & Admin13.83M20.35M25.49M29.56M31.99M
Operating Expenses58.78M80.17M114.51M137.64M143.27M
Depreciation & Amortization3.33M5.14M5.36M4.11M2.87M
EBITDA(45.3M)(59.91M)(80.1M)(119.74M)(124.13M)
EBITDA Margin-446.7%-442.6%-380.5%-4252.1%-1202.2%
Operating Income(48.64M)(66.64M)(93.46M)(134.82M)(135.81M)
Operating Margin-479.6%-492.3%-444.0%-4787.7%-1315.4%
Interest Income16K1.59M8M12.07M8.82M
Interest Expense01.18M3.76M3.65M2.77M
Other Income / Expenses16K415K4.24M7.32M6.05M
Income Before Tax(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Pre-Tax Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
Income Tax Expense00000
Net Income(48.63M)(66.22M)(89.22M)(127.5M)(129.77M)
Net Margin-479.5%-489.3%-423.9%-4527.7%-1256.8%
EPS (Basic)(2.03)(2.74)(1.36)(1.14)(1.00)
EPS (Diluted)(2.03)(2.74)(1.36)(1.14)(1.00)
Weighted Avg Shares23.91M24.05M65.6M111.99M129.86M
Weighted Avg Shares (Diluted)23.91M24.05M65.6M111.99M129.86M

TScan Therapeutics, Inc.

NASDAQ:TCRX

Intrinsic Alpha fair value

Locked

Current Price

$0.82

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.